4.7 Article

Preclinical Characterization of the 177Lu-Labeled Prostate Stem Cell Antigen (PSCA)-Specific Monoclonal Antibody 7F5

期刊

出版社

MDPI
DOI: 10.3390/ijms24119420

关键词

Lu-177-labeled antibody; prostate stem cell antigen; CHX-A ''-DTPA; prostate cancer

向作者/读者索取更多资源

Prostate specific membrane antigen (PSMA) is a promising target for imaging and treatment of prostate carcinoma (PCa), but alternative targets are needed. Prostate stem cell antigen (PSCA) is highly overexpressed in most PCa cells and correlates with tumor progression, making it a potential alternative target for theranostics. The radiolabeled antibody [Lu-177]Lu-CHX-A ''-DTPA-7F5 showed high tumor uptake and specificity in mice bearing PSCA-positive tumors, indicating its potential for imaging and radioimmunotherapy.
Prostate specific membrane antigen (PSMA) is an excellent target for imaging and treatment of prostate carcinoma (PCa). Unfortunately, not all PCa cells express PSMA. Therefore, alternative theranostic targets are required. The membrane protein prostate stem cell antigen (PSCA) is highly overexpressed in most primary prostate carcinoma (PCa) cells and in metastatic and hormone refractory tumor cells. Moreover, PSCA expression positively correlates with tumor progression. Therefore, it represents a potential alternative theranostic target suitable for imaging and/or radioimmunotherapy. In order to support this working hypothesis, we conjugated our previously described anti-PSCA monoclonal antibody (mAb) 7F5 with the bifunctional chelator CHX-A ''-DTPA and subsequently radiolabeled it with the theranostic radionuclide Lu-177. The resulting radiolabeled mAb ([Lu-177]Lu-CHX-A ''-DTPA-7F5) was characterized both in vitro and in vivo. It showed a high radiochemical purity (>95%) and stability. The labelling did not affect its binding capability. Biodistribution studies showed a high specific tumor uptake compared to most non-targeted tissues in mice bearing PSCA-positive tumors. Accordingly, SPECT/CT images revealed a high tumor-to-background ratios from 16 h to 7 days after administration of [Lu-177]Lu-CHX-A ''-DTPA-7F5. Consequently, [Lu-177]Lu-CHX-A ''-DTPA-7F5 represents a promising candidate for imaging and in the future also for radioimmunotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据